After many years of failure in searching the medicine and treatment for MASH, a thyroid hormone receptor beta (THR-β) agonist (Resmetirom) has won the marathon and been approved by the US Food and Drug Administration (FDA) [5,6]. Here, THRB is linked to metabolic dysfunction-associated steatohepatitis.